- Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
-
Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T
- KMID: 2512105
- Intest Res.
- 2021 Jan;19(1):95-105.
- doi: 10.5217/ir.2019.09167
Background/Aims: Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance... -
- CITED
-
- Close
- SHARE
-
- Close
